AI Science Tracker

Icahn School of Medicine at Mount Sinai

2 discoveries from 2023 to 2025

Discoveries

Prospective silent-trial validation of a fine-tuned pathology foundation model for EGFR mutation screening in lung adenocarcinoma

A fine-tuned Prov-GigaPath ViT-g model, named EAGLE, predicted EGFR mutation status from routine H&E slides plus clinical features in lung adenocarcinoma. Across an international dataset of 8,461 slides it achieved mean AUC 0.847 internally and 0.870 in external cohorts. In a four-month prospective silent trial on 197 primary lung-adenocarcinoma samples, EAGLE achieved AUC 0.890. Simulated AI-assisted triage thresholds reduced rapid molecular EGFR tests by up to 43% while maintaining the study’s performance criteria.

Technology: EAGLE, a task-specific model fine-tuned from the Prov-GigaPath ViT-g pathology foundation model, combining H&E whole-slide image features with clinical variables for EGFR mutation prediction

Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: prospective or independent check
  • Tested: Across an international dataset of 8,461 slides it achieved mean AUC 0.847 internally and 0.870 in external cohorts.
  • Still unknown: The four-month prospective trial was silent: AI outputs did not guide care or replace standard testing. The 43% reduction is a simulated triage workflow at a selected score threshold, not an observed reduction in tests or evidence of improved outcomes. The cohort was 197 primary cases at one real-time deployment site, while broader retrospective/external cohorts supported generalization. EAGLE predicts presence of EGFR mutation but does not identify the mutation subtype; sequencing remains necessary before treatment. Performance was lower on metastatic samples. The paper is a distinct 2025 model iteration and validation study in the lineage of the group’s 2022 arXiv proof of concept (10.48550/arXiv.2206.10573); the prior work is cited as antecedent, not treated as a second alias or hidden as the first-ever pathology-image EGFR result.
  • AI role: The AI model predicted tumor EGFR mutation status directly from routine H&E digital slides, using sequencing results as ground truth. Fine-tuning the pathology foundation model produced cross-institution validation, and real-time inference in a prospective silent trial tested generalization on newly processed clinical slides. The model score was evaluated as a screening/triage layer alongside rapid molecular testing; it did not replace genomic sequencing.

Evidence sources: https://www.nature.com/articles/s41591-025-03780-x

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 106 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 4/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Longitudinal EHR machine learning identifies patients who may need autoimmune rheumatic-disease evaluation years earlier

A random-forest model trained on longitudinal electronic health records from 161,584 people across two institutions identified records associated with high-specificity autoantibody testing for systemic autoimmune rheumatic diseases (SARDs). The model achieved AUROC 0.93 in internal validation and 0.87 on the external All of Us cohort. In a separate BioMe cohort, model probabilities tracked SARD and other autoimmune diagnoses; records could predict later autoantibody testing and rheumatology encounters up to five years before those events. The study also found higher autoantibody yield among model-prioritized individuals than under the comparison clinical-testing rate.

Technology: Random-forest machine-learning model using longitudinal electronic-health-record diagnoses, medications, laboratory results and vital signs

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: A random-forest model trained on longitudinal electronic health records from 161,584 people across two institutions identified records associated with high-specificity autoantibody testing for systemic autoimmune rheumatic diseases (SARDs).
  • Still unknown: The model predicts clinical suspicion and need for rheumatological testing, not a SARD diagnosis. The study was retrospective and opportunistic; autoantibody testing and rheumatology encounters are imperfect proxies for clinical need, and some diseases were not included in the training target. The authors state prospective studies are needed to determine whether model-guided testing improves care or outcomes. The five-year lead is retrospective prediction of later evaluation events, not proven earlier diagnosis or patient benefit.
  • AI role: The model ranked patients by probability of receiving SARD-specific autoantibody testing, using clinical data preceding the test or rheumatology encounter. Investigators evaluated performance in internal validation, the external All of Us cohort and an independent BioMe cohort, and tested whether higher scores tracked diagnosed autoimmune disease and identified later testing or encounters earlier in retrospective records.

Evidence sources: https://www.nature.com/articles/s41467-023-37996-7.pdf

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 40 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.